Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

Abstract: Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.

Abstract: Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.

Abstract: Compounds of Formula (I): salts thereof and methods of use as Janus kinase inhibitors are described herein.

Abstract: Compounds of Formula (I) and methods of use as Janus kinase inhibitors are described herein.

Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I? structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I? compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Abstract: Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.

Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.

Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

Abstract: The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a JAK kinase activity in a patient.

Abstract: A subsonic ammunition cartridge casing having an engineered internal volume designed to allow for the introduction of precisely the amount of propellant necessary at precisely the desired location to reproducibly produce the desired projectile velocity and internal pressure is provided. The subsonic shell casing has an engineered internal propellant cavity built into the internal body of the casing itself that does not necessarily depend on the introduction of a separate volume reducing device such as tubing, filler, foam filler and the like. This ensures the integrity of the case, does not result in anything being expelled through the muzzle of the weapon other than the projectile, does not have any burning or combusting components, allows for very precise control of the internal volume and thus chamber pressure, and is economical to produce.

Abstract: An ammunition cartridge casing having a geometry designed to allow for the use of polymeric materials in forming the walls of the cartridge casing of an ammunition article, and methods of reusing such cartridges are provided. More specifically, the ammunition cartridge has a specified ratio between the wall-thicknesses of select portions of an ammunition article's cartridge casing such that polymeric materials may be used in the construction of the ammunition article cartridge casings.

Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.

Abstract: An ammunition cartridge casing having a geometry designed to allow for the use of polymeric materials in forming the walls of the cartridge casing of an ammunition article, and methods of reusing such cartridges are provided. More specifically, the ammunition cartridge has a specified ratio between the wall-thicknesses of select portions of an ammunition article's cartridge casing such that polymeric materials may be used in the construction of the ammunition article cartridge casings.

Abstract: A subsonic ammunition cartridge casing having an engineered internal volume designed to allow for the introduction of precisely the amount of propellant necessary at precisely the desired location to reproducibly produce the desired projectile velocity and internal pressure is provided. The subsonic shell casing has an engineered internal propellant cavity built into the internal body of the casing itself that does not necessarily depend on the introduction of a separate volume reducing device such as tubing, filler, foam filler and the like. This ensures the integrity of the case, does not result in anything being expelled through the muzzle of the weapon other than the projectile, does not have any burning or combusting components, allows for very precise control of the internal volume and thus chamber pressure, and is economical to produce.

Abstract: An ammunition cartridge casing having a geometry designed to allow for the use of polymeric materials in forming the walls of the cartridge casing of an ammunition article, and methods of reusing such cartridges are provided. More specifically, the ammunition cartridge has a specified ratio between the wall-thicknesses of select portions of an ammunition article's cartridge casing such that polymeric materials may be used in the construction of the ammunition article cartridge casings.

Abstract: A subsonic ammunition cartridge casing having an engineered internal volume designed to allow for the introduction of precisely the amount of propellant necessary at precisely the desired location to reproducibly produce the desired projectile velocity and internal pressure is provided. The subsonic shell casing has an engineered internal propellant cavity built into the internal body of the casing itself that does not necessarily depend on the introduction of a separate volume reducing device such as tubing, filler, foam filler and the like. This ensures the integrity of the case, does not result in anything being expelled through the muzzle of the weapon other than the projectile, does not have any burning or combusting components, allows for very precise control of the internal volume and thus chamber pressure, and is economical to produce.

Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.